Heart Failure Bench to Bedside
Heart Failure (HF) is the final and common pathway of all cardiovascular diseases. Heart Failure: Bench to Bedside helps address a significant need to develop new paradigms and to identify novel therapeutic targets for this pervasive disease. An aut
- PDF / 13,571,865 Bytes
- 460 Pages / 595.276 x 790.866 pts Page_size
- 14 Downloads / 206 Views
Christopher P. Cannon, MD Series Editor Annemarie M. Armani, MD Executive Editor
For other titles published in this series, go to www.springer.com/series/7677
.
José Marín-García, MD
Heart Failure Bench to Bedside
José Marín-García, MD Director The Molecular Cardiology and Neuromuscular Institute Highland Park, NJ USA [email protected]
ISBN 978-1-60761-146-2 e-ISBN 978-1-60761-147-9 DOI 10.1007/978-1-60761-147-9 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2009943534 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Cover illustration: Untitled by Danièle M. Marín Printed on acid-free paper Humana Press is a part of Springer Science+Business Media (www.springer.com)
To my wife Danièle, and daughter Mèlanie with love
.
Preface
Heart Failure (HF), an endemic problem of great magnitude in the world, is essentially the final and common pathway of cardiovascular diseases that result in cardiac systolic and/or diastolic dysfunction. Common underlying disorders in HF include cardiomyopathy, primary or acquired from previous myocardial infarctions, chronic myocardial ischemia, hypertension, diabetes, valvular defects, dysrhythmias, and congenital heart defects. The hallmark of HF is that of relentless clinical progression often manifested as repeated hospitalizations with a significant economic impact to society. Despite considerable clinical and research advances, the morbidity and mortality of HF remain high. Consequently, there is an urgent need to develop new paradigms and to identify novel therapeutic targets for HF. While invasive and noninvasive procedures such as cardiac catheterization and echocardiography have been for several decades the most important diagnostic tools in children and adults with cardiovascular diseases, presently clinical cardiology is experiencing a period of profound transformation with advances that are changing dramatically our understanding of HF pathophysiology. Upon the completion of the Human Genome Project, new discoveries in molecular and cellular biology have begun to offer significant insights into the basic mechanisms underlying HF, and they are providing clinicians and researchers alike with a large armamentarium of new and largely effective noninvasive diagnostic techniques. With so many new and spectacula
Data Loading...
